Welcome to our dedicated page for CONEXEU SCIENCES news (Ticker: CNXU), a resource for investors and traders seeking the latest updates and insights on CONEXEU SCIENCES stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CONEXEU SCIENCES's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CONEXEU SCIENCES's position in the market.
Conexeu Sciences (Nasdaq: CNXU) outlined its strategy to enter large-volume injectable aesthetics with its investigational tissue-restoration platform CXU™, targeting currently unserved needs such as breast, hip, and buttock volume restoration at scales existing fillers do not address.
The company has completed its 12‑month P.R.O.O.F. preclinical program (Performance and Regeneration Outcomes of Flowable Collagen), evaluating CXU™ in a large-volume model and on injectable mechanical performance. According to Conexeu, CXU™ is a thermosensitive, flowable collagen scaffold designed to flow through fine needles, conform in three dimensions, and set at body temperature to support tissue regeneration. The company is pursuing a predicate-based regulatory pathway and is targeting a 510(k) submission for its lead candidate in the first quarter of 2027, subject to required testing, manufacturing, and documentation. Conexeu links its opportunity to growing breast and buttock augmentation markets and GLP‑1-driven demand for aesthetic volume restoration.
Conexeu Sciences (Nasdaq: CNXU) opened a new research and development facility at adMare BioInnovations' M4 Innovation Centre in Vancouver, Canada. The company marked the milestone with a ribbon-cutting ceremony on June 23.
The lab will focus on the CXU™ regenerative tissue platform and B.R.E.A.S.T.™, a 3D‑bioprinted breast matrix for post‑mastectomy tissue regeneration.
Conexeu (Nasdaq:CNXU) expanded its leadership following its Nasdaq listing, increasing the Board from six to nine directors and updating committee roles.
The company appointed Ana Bastiani-Posner, April Burke, and Andrew Costa to the Board, named Co-Founder David Bogart as Chief Commercial Officer, and added aesthetics expert Melinda Farina to its advisory board, supporting commercialization of its CXU™ platform and preclinical B.R.E.A.S.T.™ breast matrix.
Conexeu Sciences (Nasdaq: CNXU) reported progress in manufacturing scale up and standardized formulation for its lead CXU™ wound care device, working with a CDMO to generate materials for regulatory testing.
The company targets a 510(k) FDA submission in Q1 2027, supported by ongoing manufacturing, packaging, sterilization, and documentation activities, informed by FDA Q-Submission feedback.
Conexeu Sciences (Nasdaq: CNXU), a biotechnology company focused on tissue regeneration, will ring the Nasdaq Closing Bell on June 10, 2026, celebrating its recent public listing and trading under ticker CNXU.
The event highlights its BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE™ B.R.E.A.S.T.™ program and CXU™ platform.
Conexeu Sciences (Nasdaq: CNXU) launched a preclinical development program for its B.R.E.A.S.T.™ 3D-printed bioregenerative breast matrix at the Wake Forest Institute for Regenerative Medicine (WFIRM).
The program will use WFIRM’s bioprinting infrastructure to study durability, host tissue integration and resorbability, guiding future clinical development.
Conexeu Sciences (Nasdaq: CNXU), a biotechnology company focused on tissue regeneration, has commenced trading on the Nasdaq under ticker CNXU.
The company reports 25,269,996 issued and outstanding shares and 35,238,222 fully diluted shares, and is advancing its proprietary CXU™ regenerative tissue platform and B.R.E.A.S.T.™ 3D-bioprinted breast matrix.